# A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT05128825** · PHASE2 · RECRUITING · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 310 (estimated)

## Conditions studied

- High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

## Interventions

- **DRUG:** azenosertib

## Key facts

- **NCT ID:** NCT05128825
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-17
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05128825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05128825, "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05128825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*